Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.

J Immunother Cancer · 2019 · PMC6806565 · PMID 31640780

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.1500

boldest claim

The sentences

showed a trendP = 0.054so close (0.05 < p ≤ 0.1)

1 c) and PFS ( P = 0.002) in overall DLBCL and showed a trend towards better PFS in ABC-DLBCL ( P = 0.054; Additional file 1 : Figure S6a).

also in 53,322 other papers

marginally significantP = 0.059so close (0.05 < p ≤ 0.1)

When partitioning DLBCL into GCB and ABC subtypes, the favorable prognostic effect of IGHV SHM high was significant in ABC-DLBCL and marginally significant in BCL2 -R − and MYC -R − GCB-DLBCL (for OS, P = 0.059 and 0.066, respectively; Additional file 1 : Figure S5c-d).

also in 26,082 other papers

a nonsignificant trendP = 0.15not close (p > 0.1)

However, the prognostic effect was only significant in the validation set ( P = 0.015; it showed a nonsignificant trend in the training set of ABC-DLBCL, P = 0.15), and the number of cases with long K/LCDR3 length was small (4 and 3 in the training and validation sets, respectively).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.